Hypothesis

Acarbose extends lifespan not only by blunting post‑prandial glucose but also by raising colonic butyrate, which enters the liver, inhibits histone deacetylases (HDACs), and liberates the autophagy initiator ATG14 from lipid‑droplet sequestration. This dual action—HDAC‑dependent TFEB activation and ATG14 release—overcomes the age‑related mTORC1‑driven suppression of autophagy, restoring flux and promoting longevity.

Mechanistic Rationale

• Chronic mTORC1 hyperactivation in aging liver sustains autophagy suppression through persistent insulin‑receptor signaling (2).
• Lipid droplet accumulation with age traps ATG14 and other autophagy nucleators, making them unavailable for phagophore formation even when upstream signals are permissive.
• Butyrate, a product of fiber fermentation elevated by acarbose (4), is a known HDAC inhibitor that increases acetylation of TFEB, driving its nuclear translocation and lysosomal biogenesis (5).
• Increased TFEB activity upregulates lysosomal genes and promotes lipophagy, the selective autophagy of lipid droplets, thereby freeing sequestered ATG14.
• Free ATG14 can now associate with the PI3K‑complex, initiating phagophore assembly despite ongoing mTORC1 activity, especially when acarbose‑derived butyrate concurrently activates AMPK (5), which inhibits mTORC1 at the lysosomal surface.

Thus, butyrate tackles autophagy suppression on two fronts: (1) epigenetic re‑programming that boosts lysosomal capacity, and (2) lipid‑droplet clearance that releases the core autophagy machinery.

Testable Predictions

1. Aged mice treated with acarbose will show increased hepatic butyrate levels, higher TFEB acetylation, and reduced lipid‑droplet burden compared with vehicle controls.
2. ATG14 will shift from a lipid‑droplet‑associated to a cytosolic/punctate distribution in acarbose‑treated livers, detectable by immunofluorescence co‑localization assays.
3. Pharmacologic HDAC inhibition (e.g., with sodium butyrate) alone will mimic acarbose’s effect on ATG14 localization and autophagic flux, whereas HDAC overexpression will blunt it.
4. Genetic attenuation of lipophagy (e.g., liver‑specific ATG14 knockout) will abolish the lifespan extension seen with acarbose‑rapamycin combination, despite persistent AMPK activation.
5. AMPK activation alone (e.g., AICAR) will increase autophagic flux but will not reduce lipid‑droplet size or release ATG14, indicating that the lipid‑droplet arm is essential for the full effect.

Experimental Design

• Animal cohorts: 20‑month‑old C57BL/6 mice (both sexes) assigned to: (i) control, (ii) acarbose, (iii) sodium butyrate (dose matched to fecal levels from acarbose group), (iv) acarbose + HDAC activator (e.g., nicotinamide), (v) acarbose + lipophagy inhibitor (e.g., ATG14 liver‑KO). Treat for 6 months.
• Readouts: hepatic butyrate (GC‑MS), TFEB acetylation (immunoprecipitation‑Western), lipid‑droplet area (BODIPY staining, ImageJ), ATG14 subcellular localization (confocal microscopy, Pearson’s coefficient with perilipin‑2), autophagic flux (LC3‑II turnover with bafilomycin A1, p62 levels), and survival.
• Statistical analysis: Two‑way ANOVA with post‑hoc Tukey for endpoint comparisons; Kaplan‑Meier with log‑rank test for lifespan.

Potential Outcomes and Interpretation

• If predictions hold, the data will support a model where acarbose‑derived butyrate restores autophagy by coupling HDAC‑mediated transcriptional reprogramming with lipid‑droplet clearance, thereby releasing sequestered ATG14. This would explain the synergistic longevity of acarbose + rapamycin: rapamycin dampens mTORC1 downstream, while butyrate removes upstream lipid‑droplet and epigenetic brakes.
• If ATG14 remains lipid‑droplet‑bound despite increased butyrate/TFEB activity, the hypothesis would be falsified, suggesting that acarbose’s longevity benefit operates through alternative pathways (e.g., systemic inflammation modulation or intestinal barrier improvement).
• If HDAC inhibition alone fails to extend lifespan, it would indicate that both epigenetic and lipid‑droplet mechanisms are required, emphasizing the combinatorial nature of the intervention.

This hypothesis is directly falsifiable, leverages existing ITP data, and provides a clear mechanistic bridge between microbiome‑derived metabolites and the cell‑autonomous autophagy machinery that falters with age.